SCHEMBL4293358

SCHEMBL4293358

Cc1cc(C(=O)Cc2ccc(F)cc2)nc2c1OCC(=O)N2

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 9/20 0.40
PGR P06401 6/20 0.40
MAPT P10636 3/20 0.39
NR3C1 P04150 6/20 0.38
ADRB2 P07550 3/20 0.37
ADRB1 P08588 2/20 0.37
LMNA P02545 2/20 0.37
HTT P42858 2/20 0.37
MEN1 O00255 1/20 0.37
TSHR P16473 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MGLL Q99685 1/20 0.35
KDM4E B2RXH2 1/20 0.34
TP53 P04637 1/20 0.34
ALOX15 P16050 1/20 0.34
MAPK1 P28482 1/20 0.34
HSD17B10 Q99714 1/20 0.34
AR P10275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4763929 0.85 P2RX7 (0.38) NR3C2PGRNR3C1MGLLAR
SCHEMBL4286243 0.80 NR3C2 (0.48) NR3C2PGRMAPTNR3C1ADRB2
SCHEMBL8231796 0.80 NR3C2 (0.39) NR3C2PGRMAPTNR3C1ADRB2
SCHEMBL4286650 0.79 NR3C2 (0.39) NR3C2PGRMAPTNR3C1ADRB2
SCHEMBL4286817 0.77 NR3C2 (0.36) NR3C2PGRMAPTNR3C1LMNA
SCHEMBL4286608 0.75 NR3C2 (0.46) NR3C2PGRMAPTNR3C1ADRB2
SCHEMBL4291854 0.74 ALDH1A1 (0.37) NR3C2MAPTLMNAMEN1TSHR
SCHEMBL4290378 0.72 ALDH1A1 (0.47) NR3C2PGRMAPTNR3C1ADRB2
SCHEMBL4286990 0.70 NR3C2 (0.34) NR3C2PGR
SCHEMBL14476438 0.70 KCNH2 (0.38) NR3C2PGRNR3C1ADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 US disclosed
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 US disclosed
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 US disclosed
WO-2007077961-A2 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands NR3C2, NR3C1, MC2R NR3C2 1/4885PGR 408/4885MAPT 4442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.